Treatment with levodopa and risk for malignant melanoma.
ABSTRACT A large follow-up study in Denmark of 14,088 patients in whom Parkinson's disease was diagnosed at hospital showed a twofold higher incidence of malignant melanoma in these patients than in the general population. In a nested case-control study of 45 patients with malignant melanoma, 97 patients with nonmelanoma skin cancer, and 172 control subjects, we investigated the hypothesis that treatment with levodopa increases the risk for skin cancer. Information on diagnoses and treatment was retrieved from medical records. We observed a significant fourfold to fivefold increase in the risk for malignant melanoma in a subgroup of patients with a probable diagnosis of idiopathic Parkinson's disease as compared with other patients. There was apparently no effect of levodopa on the risk for malignant melanoma as indicated by an odds ratio of 1.0 (95% confidence interval, 0.8-1.3) per 1,000 g cumulative intake of the drug. We conclude that the increased rate of malignant melanoma observed in patients treated at hospital for Parkinson's disease is restricted to those with idiopathic Parkinson's disease, however, unrelated to the treatment with levodopa.
- Actas Dermo-Sifiliográficas 01/2010; 101(1):95–96.
- [Show abstract] [Hide abstract]
ABSTRACT: Globally, malignant melanoma shows a steady increase in the incidence among cancer diseases. Malignant melanoma represents a cancer type where currently no biomarker or diagnostics is available to identify disease stage, progression of disease or personalized medicine treatment. The aim of this study was to assess the tissue expression of alpha-synuclein, a protein implicated in several disease processes, in metastatic tissues from malignant melanoma patients. A targeted Selected Reaction Monitoring (SRM) assay was developed and utilized together with stable isotope labeling for the relative quantification of two target peptides of alpha-synuclein. Analysis of alpha-synuclein protein was then performed in ten metastatic tissue samples from the Lund Melanoma Biobank. The calibration curve using peak area ratio (heavy/light) versus concentration ratios showed linear regression over three orders of magnitude, for both of the selected target peptide sequences. In support of the measurements of specific protein expression levels, we also observed significant correlation between the protein and mRNA levels of alpha-synuclein in these tissues. Investigating levels of tissue alpha-synuclein may add novel aspect to biomarker development in melanoma, help to understand disease mechanisms and ultimately contribute to discriminate melanoma patients with different prognosis.PLoS ONE 10/2014; · 3.53 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Zusammenfassung ▼ Der Zusammenhang zwischen Idiopathischen Parkinson-Syndrom (IPS), L-Dopa-Therapie und malignem Melanom wirft weiterhin Fragen auf. Aus diesem Grund wurde von uns eine Studie mit 712 Parkinson-Patienten aus der Klinik und Poliklinik für Neurologie des Universitätsklinikum Hamburg-Eppendorf durchgeführt, die einerseits zeigte, dass IPS-Patienten formal statistisch ein 1-bis zu 4-fach erhöhtes Melanomrisiko haben und andererseits, dass eine L-Dopa Therapie die Entstehung eines Melanoms nicht ursächlich zu fördern scheint. Abstract ▼ The relationship between Parkinson's disease (PD), L-dopa therapy and melanoma is still a topic of some controversy. For this reason we have conducted a study with 712 PD patients of the Department of Neurology in the University Hospital Hamburg-Eppendorf. It showed, on the one hand, that PD patients have statistically a 4-times increased risk to develop a melanoma while, on the other hand, that an L-dopa therapy does not promote the development of melanoma.Aktuelle Neurologie 08/2013; 40:309-314. · 0.32 Impact Factor